Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer

被引:13
|
作者
Hellstrom, M
Ranefall, P
Wester, K
Brandstedt, S
Busch, C
机构
[1] KAROLINSKA INST,DANDERYD HOSP,DEPT UROL,UPPSALA,SWEDEN
[2] UPPSALA UNIV,CTR IMAGE ANAL,UPPSALA,SWEDEN
[3] UNIV HOSP,DEPT PATHOL,UPPSALA,SWEDEN
来源
BRITISH JOURNAL OF UROLOGY | 1997年 / 79卷 / 03期
关键词
localized prostate cancer; neoadjuvant androgen deprivation; cancer volume; planimetry; immunohistochemistry; colour image analysis;
D O I
10.1046/j.1464-410X.1997.02920.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To measure the area distribution of epithelial and mesenchymal components in the prostate of patients with localized prostate cancer after temporary androgen deprivation. Patients and methods Surgical specimens from 38 patients treated with the gonadotrophin-releasing hormone agonist triptorelin for 3 months before radical prostatectomy were examined (group 1). Specimens from a second group of 54 patients who underwent the same surgical procedure with no prior therapy were used as controls (group 2). The specimens were serially step-sectioned and whole-mount tissue sections prepared. The epithelial, smooth muscle and connective tissue components were stained separately with immunohistochemical and histochemical techniques, respectively. Using colour-based image analyses, the tissue components were classified into three categories, displayed in different colours. The percentage of tumour areas occupied by cancer epithelial cells, connective tissue and smooth muscle was determined. Results In specimens from group 1, the cancer epithelium was sparse and scattered throughout the tumour area. A mean (so) of 21 (11)% of the area was occupied by cancer cells, compared with 40 (11)% in the corresponding material from group 2 (P<0.001). The connective tissue/smooth muscle ratio in stroma (about 1 : 1) was similar in both groups. Conclusions Neoadjuvant hormone treatment of patients with localized prostate cancer was associated with a marked reduction in tumour density and thus in the total amount of cancer epithelium.
引用
收藏
页码:421 / 426
页数:6
相关论文
共 50 条
  • [22] Outcomes of androgen deprivation as sole therapy for localized prostate cancer.
    Janoff, D
    Mongoue-Tchokote, S
    Peterson, C
    Parra, RO
    Peters, L
    Park, Y
    Beer, TM
    Mori, M
    Garzotto, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 413S - 413S
  • [23] THE EFFECT OF ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER ON CARDIOVASCULAR MORBIDITY ACCORDING TO LIFE EXPECTANCY
    Schmid, Marianne
    Sammon, Jesse
    Reznor, Gally
    Kapoor, Victor
    Speed, Jaqueline
    Abdollah, Firas
    Sood, Akshay
    Chun, Felix
    Kibel, Adam
    Menon, Mani
    Fisch, Margit
    Sun, Maxine
    Quoc-Dien Trinh
    JOURNAL OF UROLOGY, 2015, 193 (04): : E657 - E657
  • [24] Re: Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
    Parker, Chris
    EUROPEAN UROLOGY, 2011, 60 (06) : 1306 - 1306
  • [25] Re: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality
    Mongiat-Artus, Pierre
    EUROPEAN UROLOGY, 2008, 53 (06) : 1297 - 1297
  • [26] Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events
    Schmid, Marianne
    Sammon, Jesse D.
    Reznor, Gally
    Kapoor, Victor
    Speed, Jacqueline M.
    Abdollah, Firas A.
    Sood, Akshay
    Chun, Felix K. -H.
    Kibel, Adam S.
    Menon, Mani
    Fisch, Margit
    Sun, Maxine
    Trinh, Quoc-Dien
    BJU INTERNATIONAL, 2016, 118 (02) : 221 - 229
  • [27] INTERMITTENT ANDROGEN DEPRIVATION AS SECONDARY THERAPY FOR BIOCHEMICAL RECURRENCE OF LOCALIZED PROSTATE CANCER
    Sanchez-Salas, R. E.
    Prapotnich, D.
    Secin, F. P.
    Favaretto, R.
    Flamand, V
    Rozet, F.
    Galiano, M.
    Barret, E.
    Cathelineau, X.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 91 - 92
  • [28] Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer
    Yang, D. D.
    Krasnova, A.
    Nead, K. T.
    Choueiri, T. K.
    Hu, J. C.
    Hoffman, K. E.
    Yu, J. B.
    Spratt, D. E.
    Feng, F. Y.
    Trinh, Q. -D.
    Nguyen, P. L.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 386 - 391
  • [29] Cardiovascular Disease Risk and Androgen Deprivation Therapy in Patients with Localized Prostate Cancer
    Haque, Reina
    Xu, Xiaoqing
    Yood, Marianne Ulcickas
    Cassidy-Bushrow, Andrea E.
    Van den Eeden, Stephen K.
    Potosky, Arnold L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 323 - 324
  • [30] Should patients with localized prostate cancer receive primary androgen deprivation therapy?
    Namiki, Mikio
    Mizokami, Atsushi
    Akaza, Hideyuki
    NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (12): : 648 - 649